P. Velden

发表

Anti-angiogenic therapy in uveal melanoma

M. Filali, P. Velden, 2012 .

Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds

L. Sandkuijl, A. Kamb, N. Gruis, 1995, Nature Genetics.

Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma

E. Jordanova, D. Toncheva, N. Gruis, 2007, Journal of Cancer Research and Clinical Oncology.

Epigenetic Inactivation of RASSF 1 a in Uveal Melanoma

N. Gruis, M. Jager, W. Maat, 2007 .

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS

N. Hayward, S. Pavey, M. Stark, 2005, British Journal of Cancer.

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden)

N. Gruis, W. Bergman, R. Frants, 2000, International journal of cancer.

Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.

J. Harbour, M. Dogrusöz, M. Jager, 2015, Investigative ophthalmology & visual science.

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes

C. Laurent, Sake I. van Pelt, G. Luyten, 2016, PloS one.

Effect of hypoxic stress on induction and plasticity of tumor-induced immune cells in uveal melanoma

P. V. Velden, G. Luyten, M. Jager, 2013 .

Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma.

L. Sandkuijl, N. Gruis, W. Bergman, 2001, American journal of human genetics.

Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.

N. Gruis, W. Bergman, R. Frants, 2001, Cancer research.

Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study

S. Puig, E. Gillanders, D. Elder, 2010, Journal of the National Cancer Institute.